slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 86,191-86,220
Pages 3,225
Rows per page 30
Component
86,191-86,220 of 96,741
09
The slide uses a comparative framework to position the drug as a superior alternative to existing checkpoint inhibitors.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
10
The slide uses a diagram of an antibody to map specific functional regions to their biological mechanisms.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
12
The slide uses a simple additive framework to show how immune response and clinical activity lead to a strategic positioning as a 'backbone' therapy.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
15
Spider plot (swimmer plot variant) showing individual patient responses over time.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
16
The slide uses a before-and-after medical imaging comparison to validate clinical efficacy.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
17
Includes Kaplan-Meier survival curve and comparative efficacy tables.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
18
Includes a timeline of biopsy (Bx) and treatment, and paired dot plots showing pre/post treatment changes in CD68+ and CD3+ cell counts.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
19
Spider plot (swimmer plot variant) showing individual patient tumor response trajectories.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
22
The slide uses a biological process diagram to illustrate the mechanism of action.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
25
The slide uses a three-pillar structure supported by a foundational platform.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
05
The chart uses a dual-line comparison to show the divergence in risk outcomes based on treatment timing.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
12
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
07
The slide uses a visual comparison of biological mechanisms to argue for the superiority of the company's 'Decoy AXL Receptor' approach.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
08
The slide uses a two-column layout to contrast the drug's engineering/profile with its biomarker/IP strategy.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
06
The slide uses iconography to represent key statistics about rare diseases.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle1 hit
12
The slide uses a biological process flow to explain the therapeutic rationale for C5 inhibition.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
18
Includes 'Number at risk' table below the x-axis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
19
The slide uses a Kaplan-Meier survival curve for HSCT-TMA and market sizing metrics for CSA-AKI.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
21
Comparison of molecular weight (25 kDa vs 150 kDa) and administration method.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
22
Includes clinical trial design diagram for Part A and Part B.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
23
Includes a biological pathway diagram and a comparison of circulating concentrations.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
25
Includes FDA Breakthrough Designation callout and trial design diagrams.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
28
Uses a pictograph to represent patient population segments.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
29
The chart shows a comparison of branded vs unbranded/off-label market size over time, and a pie chart showing patient source.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
30
The slide uses a combination of scientific evidence (left) and market/trial status (right) to justify investment.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
35
The slide uses a Venn-style diagram to illustrate market expansion.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
36
The slide uses a process diagram to illustrate the pathophysiology of two distinct types of amyloidosis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
37
The slide uses a comparative structure to map assets to specific disease indications and their clinical progress.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
05
The slide uses a hierarchical structure to connect a high-level objective to three distinct operational pillars.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
20
The slide uses a combination of a problem overview, a global impact section, and a 'huge need' vertical timeline/list.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit